专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2005072306A2 REELIN DEFICIENCY OR DYSFUNCTION AND METHODS RELATED THERETO 审中-公开
标题翻译：重组缺陷或功能障碍及其相关方法
公开(公告)号：WO2005072306A2
公开(公告)日：2005-08-11
申请号：PCT/US2005/002177
申请日：2005-01-19
申请人： MARTEK BIOSCIENCES CORPORATION , MORSEMAN, John, P. , MOSS, Mark, W. , ELLIS, Lorie, A.
发明人： MORSEMAN, John, P. , MOSS, Mark, W. , ELLIS, Lorie, A.
CPC分类号： A61K31/20
摘要： A method of measuring Reelin as a biomarker, to non-destructively assess or predict DHA levels in the brain and in other, currently inaccessible or difficult-to-access, key components of the central nervous system (CNS) is described. Also described is a method to prevent, delay the onset of, or treat Reelin deficiency or dysfunction and/or a disease or condition associated with Reelin deficiency or dysfunction, comprising administering to a patient diagnosed with or suspected of having a Reelin deficiency or dysfunction an amount of a PUFA, and particularly an omega-3 PUFA, and more particularly, docosahexaenoic acid (DHA) or a precursor or source thereof, to compensate for the effects of Reelin deficiency or dysfunction in the patient. Also described is a method to prevent or reduce development defects or disorders associated with Reelin dysfunction or deficiency through the supplemental use of polyunsaturated fatty acids (PUFAs- unsaturated fatty acids having two or more double bonds), and particularly highly unsaturated fatty acids (HUFAs- unsaturated fatty acids having three or more double bonds), and more particularly a HUFA selected from arachidonic acid (ARA), eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA) and docosapentaenoic acid (DPA), and even more particularly omega-3 HUFAs, and more particularly DHA, to: compensate for reduced fatty acid binding protein or function thereof in the patient; compensate for reduced brain lipid binding protein or function thereof in the patient; improve the activity of fatty acid binding proteins in the patient; increase the expression of brain lipid binding proteins (BLBPs) in the patient; improve at least one parameter of the mechanism of action of brain lipid binding proteins in the patient; overcome a deficiency of DHA in central nervous system (CNS) structures and improve the resulting function thereof; increase the incorporation of functional DHA and other PUFAs into the phospholipid membranes of glial cells and neurons in the patient; increase the level of Reelin and/or improve the activity of Reelin in the patient; and/or improve at least one symptom of a disease or condition associated with Reelin deficiency or dysfunction.
摘要翻译：描述了测量作为生物标志物的Reelin的方法，以非破坏性地评估或预测中枢神经系统（CNS）的大脑和其他目前难以接近或难以进入的关键组分中的DHA水平。还描述了一种防止，延迟开始或治疗Reelin缺陷或功能障碍和/或与Reelin缺陷或功能障碍相关的疾病或病症的方法，包括对诊断患有或怀疑具有Reelin缺陷或功能障碍的患者施用 PUFA，尤其是ω-3 PUFA，尤其是二十二碳六烯酸（DHA）或其前体或来源的量，以补偿患者的Reelin缺陷或功能障碍的作用。还描述了通过补充使用多不饱和脂肪酸（具有两个或更多个双键的PUFA-不饱和脂肪酸），特别是高度不饱和脂肪酸（HUFAs-不饱和脂肪酸）来预防或减少与Reelin功能障碍或缺陷相关的发育缺陷或障碍的方法，更具体地说，选自花生四烯酸（ARA），二十碳五烯酸（EPA），二十二碳六烯酸（DHA）和二十二碳五烯酸（DPA），甚至更特别是ω-3 HUFA的HUFA的不饱和脂肪酸更具体地，DHA，以补偿患者中的降低的脂肪酸结合蛋白或其功能; 补偿患者脑组织中的脂质结合蛋白或其功能; 改善患者脂肪酸结合蛋白的活性; 增加患者脑部脂质结合蛋白（BLBPs）的表达; 改善患者脑组织结合蛋白的作用机制的至少一个参数; 克服中枢神经系统（CNS）结构中DHA的缺陷，改善其功能; 增加功能性DHA和其他PUFA掺入患者胶质细胞和神经元的磷脂膜中; 增加Reelin的水平和/或改善患者的Reelin的活性; 和/或改善与Reelin缺陷或功能障碍相关的疾病或病症的至少一种症状。

2. 发明申请

WO0196871A2 RECOMBINANT PHYCOBILIPROTEIN AND PHYCOBILIPROTEIN LINKER FUSION PROTEINS AND USES THEREFORE 审中-公开
标题翻译：重组蛋白和蛋白质连接蛋白融合蛋白及其用途
公开(公告)号：WO0196871A2
公开(公告)日：2001-12-20
申请号：PCT/US0119439
申请日：2001-06-18
申请人： MARTEK BIOSCIENCES CORP , ALLNUTT F C THOMAS , TOOLE COLLEEN M , MORSEMAN JOHN P
发明人： ALLNUTT F C THOMAS , TOOLE COLLEEN M , MORSEMAN JOHN P
IPC分类号： C07K14/195 , C07K14/405 , G01N33/533 , G01N33/542 , G01N33/53
CPC分类号： C07K14/195 , C07K14/405 , C07K2319/00 , G01N33/533 , G01N33/542
摘要： This invention is directed to the utilization of the developing methods for molecular manipulation of cyanobacteria and red algae (and potentially cryptomonad algae) to express of phycobiliproteins and phycobiliprotein linker fusion proteins and their utilization as phycobiliprotein, phycobilisome and subassembly based reagents. In particular, the present invention relates to a method for a specific binding assay to determine a target moiety which is a member of a specific binding pair, and provides an improvement in the method comprising using a detectable label which is a fusion protein containing both a phycobiliprotein domain and another domain corresponding to a first member of a specific binding pair, where the fusion protein binds to a second member of the specific binding pair to provide a detectable labeled complex. The domain derived from the first member of the specific binding pair can be directly fused to the phycobiliprotein or phycobiliprotein linker domain or be separated by a spacer that allows correct folding of both domains.
摘要翻译：本发明涉及利用蓝藻和红藻（和潜在的cryptomonad藻类）的分子操作的表达方法来表达藻胆蛋白和藻胆蛋白连接体融合蛋白，以及它们作为藻胆蛋白，藻糖酵母和基于组件的试剂的利用。特别地，本发明涉及用于确定作为特异性结合对成员的靶部分的特异性结合测定方法，并且提供了该方法的改进，该方法包括使用可检测标记，其是含有两者的融合蛋白藻类蛋白结构域和对应于特异性结合对的第一个成员的另一个结构域，其中融合蛋白与特异性结合对的第二个成员结合以提供可检测的标记复合物。衍生自特异性结合对的第一个成员的结构域可以直接融合到藻胆蛋白或藻胆蛋白连接体结构域，或者被允许正确折叠两个结构域的间隔物分离。

3. 发明申请

WO0196383A3 HIGH FLUORESCENT INTENSITY CROSS-LINKED ALLOPHYCOCYANIN 审中-公开
标题翻译：高荧光强度交联的异环鸟苷
公开(公告)号：WO0196383A3
公开(公告)日：2002-04-11
申请号：PCT/US0119440
申请日：2001-06-18
申请人： MARTEK BIOSCIENCES CORP , MORSEMAN JOHN P , MOSS MARK W , ALLNUTT F C THOMAS
发明人： MORSEMAN JOHN P , MOSS MARK W , ALLNUTT F C THOMAS
IPC分类号： G01N33/533 , G01N33/542 , G01N33/58
CPC分类号： G01N33/582 , G01N33/533 , G01N33/542
摘要： In a method for quantitating an analyte by measuring time resolved transfer of fluorescence energy to or from a label quantitatively associated with the analyte, the present invention provides an improvement comprising measuring the energy transferred from donor compounds having the ability to absorb light energy and then transfer this energy to cross-linked allophycocyanin in a time-resolved manner, where the cross-linked allophycocyanin used according to this invention has not been exposed to strongly chaotropic agents after cross-linking.
摘要翻译：在通过测量与分析物定量相关的标记物的荧光能量的时间分辨转移的方法来定量分析物的方法，本发明提供了一种改进，其包括测量从具有吸收光能并且然后转移的能力的给体化合物转移的能量该能量以时间分辨的方式交联别藻蓝蛋白，其中根据本发明使用的交联别藻蓝蛋白在交联后未暴露于强离液剂。

4. 发明申请

WO2005072306A3 REELIN DEFICIENCY OR DYSFUNCTION AND METHODS RELATED THERETO 审中-公开
标题翻译：重组缺陷或功能障碍及其相关方法
公开(公告)号：WO2005072306A3
公开(公告)日：2006-03-09
申请号：PCT/US2005002177
申请日：2005-01-19
申请人： MARTEK BIOSCIENCES CORP , MORSEMAN JOHN P , MOSS MARK W , ELLIS LORIE A
发明人： MORSEMAN JOHN P , MOSS MARK W , ELLIS LORIE A
IPC分类号： A61K31/20
CPC分类号： A61K31/20
摘要： A method of measuring Reelin as a biomarker, to non-destructively assess or predict DHA levels in the brain and in other, currently inaccessible or difficult-to-access, key components of the central nervous system (CNS) is described. Also described is a method to prevent, delay the onset of, or treat Reelin deficiency or dysfunction and/or a disease or condition associated with Reelin deficiency or dysfunction, comprising administering to a patient diagnosed with or suspected of having a Reelin deficiency or dysfunction an amount of a PUFA, and particularly an omega-3 PUFA, and more particularly, docosahexaenoic acid (DHA) or a precursor or source thereof, to compensate for the effects of Reelin deficiency or dysfunction in the patient. Also described is a method to prevent or reduce development defects or disorders associated with Reelin dysfunction or deficiency through the supplemental use of polyunsaturated fatty acids (PUFAs- unsaturated fatty acids having two or more double bonds), and particularly highly unsaturated fatty acids (HUFAs- unsaturated fatty acids having three or more double bonds), and more particularly a HUFA selected from arachidonic acid (ARA), eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA) and docosapentaenoic acid (DPA), and even more particularly omega-3 HUFAs, and more particularly DHA, to: compensate for reduced fatty acid binding protein or function thereof in the patient; compensate for reduced brain lipid binding protein or function thereof in the patient; improve the activity of fatty acid binding proteins in the patient; increase the expression of brain lipid binding proteins (BLBPs) in the patient; improve at least one parameter of the mechanism of action of brain lipid binding proteins in the patient; overcome a deficiency of DHA in central nervous system (CNS) structures and improve the resulting function thereof; increase the incorporation of functional DHA and other PUFAs into the phospholipid membranes of glial cells and neurons in the patient; increase the level of Reelin and/or improve the activity of Reelin in the patient; and/or improve at least one symptom of a disease or condition associated with Reelin deficiency or dysfunction.
摘要翻译：描述了测量作为生物标志物的Reelin的方法，以非破坏性地评估或预测中枢神经系统（CNS）的大脑和其他目前难以接近或难以进入的关键组分中的DHA水平。还描述了一种防止，延迟开始或治疗Reelin缺陷或功能障碍和/或与Reelin缺陷或功能障碍相关的疾病或病症的方法，包括对诊断患有或怀疑具有Reelin缺陷或功能障碍的患者施用 PUFA，尤其是ω-3 PUFA，尤其是二十二碳六烯酸（DHA）或其前体或来源的量，以补偿患者的Reelin缺陷或功能障碍的作用。还描述了通过补充使用多不饱和脂肪酸（具有两个或更多个双键的PUFA-不饱和脂肪酸），特别是高度不饱和脂肪酸（HUFAs-不饱和脂肪酸）来预防或减少与Reelin功能障碍或缺陷相关的发育缺陷或障碍的方法，更具体地说，选自花生四烯酸（ARA），二十碳五烯酸（EPA），二十二碳六烯酸（DHA）和二十二碳五烯酸（DPA），甚至更特别是ω-3 HUFA的HUFA的不饱和脂肪酸更具体地，DHA，以补偿患者中的降低的脂肪酸结合蛋白或其功能; 补偿患者脑组织中的脂质结合蛋白或其功能; 改善患者脂肪酸结合蛋白的活性; 增加患者脑部脂质结合蛋白（BLBPs）的表达; 改善患者脑组织结合蛋白的作用机制的至少一个参数; 克服中枢神经系统（CNS）结构中DHA的缺陷，改善其功能; 增加功能性DHA和其他PUFA掺入患者胶质细胞和神经元的磷脂膜中; 增加Reelin的水平和/或改善患者的Reelin的活性; 和/或改善与Reelin缺陷或功能障碍相关的疾病或病症的至少一种症状。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式